WHO Report Shows Increase in HIV Drug Resistance to Dolutegravir
The World Health Organization’s HIV Drug Resistance Report reveals growing drug resistance in populations receiving dolutegravir-containing antiretroviral therapy (ART). However, levels of HIVDR to DTG are exceeding clinical trials. The report recommends dolutegravir as the preferred treatment due to its effectiveness, ease of use, and genetic barrier to resistance. Resistance to dolutegravir ranges from 3.9% to 8.6%, reaching 19.6% among those with high viral loads.
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
 |
BD |
AMR NEWS
Your Biweekly Source for Global AMR Insights!
Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.
Don’t miss out on staying ahead in the global AMR movement—subscribe now!